Working Group on New TB Drugs - Projects

Projects

Working Group on New TB Drugs R&D Activity Surveys

A robust and sustained pipeline of TB drug candidates and discovery programs is essential to successful development of new TB drug regimens. TB must be treated with a combination of drugs, thus prospective new drugs must be evaluated for compatibility and complementarity. With the aim of increasing efficiency and coordination of the global TB drug R&D enterprise through information-exchange, the WGND conducts an annual survey of the TB drug R&D activities of WGND members. This exercise also identifies critical gaps in resources and capacity.

About the 2008 Portfolio: Purpose and Criteria for Inclusion

For the purpose of this particular survey, WGND members were asked to submit information on clinical and preclinical development programs in progress as well as ongoing drug discovery projects (at the high throughput screening, hit to lead or lead optimization stage), including projects that address new indications for existing drugs or chemical optimization/ reformulation of currently available drugs. The 2008 chart lists the projects brought to the Group’s attention that meet these criteria and provide specific information about the activity, e.g. a compound, target, trial or screen name.

Portfolio Updates and Publication of Full Survey Results

The 2008 portfolio chart will be updated as needed, and, at least at quarterly intervals, in response to additions and changes submitted by WGND members.
To add or update information please go to http://www.tballiance.org/working-group/activity-form-new.php

In addition, detailed information submitted on each project will be published as a compendium, via this website, by December 31 2008

Additional Surveys Planned for 2009 - Watch this Space!

The 2008 portfolio reflects only a portion of Global TB drug R&D activities and only a fraction of WGND member activities impacting TB drug R&D. In 2009, the WGND will attempt additional surveys to catalog (1) Global TB drugs R&D activities and (2) WGND member capabilities and projects.